ArticleVector borne and zoonotic diseases (Larchmont, N.Y.)2018
Powassan Virus Disease in the United States, 2006-2016.
Article in Vector borne and zoonotic diseases (Larchmont, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From flyways to foci: a systematic review and meta-analysis on the role of birds in the maintenance and global dispersal of ticks and tick-borne pathogens.Parasites & vectors · 2026Pooled it
- Lyme Disease and Other Tick-Borne Infections.Current neurology and neuroscience reports · 2026Review
- Pathogenesis and neurotropism of a contemporary Powassan virus lineage II strain in mice.Journal of virology · 2026Article
- Powassan Virus in the United States: An AI-Integrative One Health Scoping Review of Ecological Drivers, Zoonotic Interactions, Symptom Profiles, and Public Health Implications.Infectious disease reports · 2026Review
- Arboviral infections of the central nervous system: Mechanisms of invasion and long-term consequences.Journal of neurovirology · 2026Review
- Article
- Powassan Virus Seroprevalence in a U.S. Servicemember Population at High Risk for Tick Exposure.medRxiv : the preprint server for health sciences · 2026Article
- Delays in Diagnosis of Powassan Virus Encephalitis-Vermont, 2022-2023.Open forum infectious diseases · 2026Article
- Pathogenicity and virulence of Powassan virus.Virulence · 2025Review
- Tick-induced neurological disorders.Journal of neurology · 2025Review
- Atomic-resolution structure of a chimeric Powassan tick-borne flavivirus.Science advances · 2025Article
- TITAN-RNA: A hybrid-capture sequencing panel detects known and unknownbioRxiv : the preprint server for biology · 2025Article
- Powassan and Eastern Equine Encephalitis Virus Seroprevalence in Endemic Areas, United States, 2019-2020.Emerging infectious diseases · 2025Article
- Article
- Article
- Age-dependent Powassan virus lethality is linked to glial cell activation and divergent neuroinflammatory cytokine responses in a murine model.Journal of virology · 2024Article
- Immunoinformatics and computational approaches driven designing a novel vaccine candidate against Powassan virus.Scientific reports · 2024Article
- Tick bite risk factors and prevention measures in an area with emerging Powassan virus disease.Public health challenges · 2023Article
- Identification and characterization of novel lineage 1 Powassan virus strains in New York State.Emerging microbes & infections · 2023Article
- The Brief Case: An unexpected cause of meningoencephalitis in an infant.Journal of clinical microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPowassan virus (POWV) is a tick-borne flavivirus that causes rare, but often severe, disease in humans. POWV neuroinvasive disease was added to the U.S. nationally notifiable disease list in 2001 and nonneuroinvasive disease was added in 2004. The only previous review of the epidemiology of POWV disease in the United States based on cases reported to the Centers for Disease Control and Prevention (CDC) covered the period from 1999 through 2005.
methodsWe describe the epidemiology and clinical features of laboratory-confirmed POWV disease cases reported to CDC from 2006 through 2016.
resultsThere were 99 cases of POWV disease reported during the 11-year period, including 89 neuroinvasive and 10 nonneuroinvasive disease cases. There was a median of seven cases per year (range: 1-22), with the highest numbers of cases reported in 2011 (n = 16), 2013 (n = 15), and 2016 (n = 22). Cases occurred throughout the year, but peaked in May and June. Cases were reported primarily from northeastern and north-central states. Overall, 72 (73%) cases were in males and the median age was 62 years (range: 3 months-87 years). Of the 11 (11%) cases who died, all were aged >50 years. The average annual incidence of neuroinvasive POWV disease was 0.0025 cases per 100,000 persons.
conclusionsPOWV disease can be a severe disease and has been diagnosed with increased frequency in recent years. However, this might reflect increased disease awareness, improved test availability, and enhanced surveillance efforts. Clinicians should consider POWV disease in patients presenting with acute encephalitis or aseptic meningitis who are resident in, or have traveled to, an appropriate geographic region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.